// App-Quantinova.ai

ABS181 : REAL‐WORLD SAFETY AND EFFECTIVENESS OF RECOMBINANT B‐DOMAIN–DELETED PORCINE‐SEQUENCE FACTOR VIII FOR ACQUIRED HEMOPHILIA A

Researchers

Presenter

  • W. Miesbach

Principal Investigators

  • P. Knoebl

  • R. Santoro

  • J. Chen

  • N. Tripkovic

  • C. L. Percy

  • A. H. Schmaier

  • R. Klamroth

Medical Centers

  • Medical Clinic II, University Hospital, Frankfurt, Germany

  • Dept. of Medicine I, Div. of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

  • Hemostasis and Thrombosis Unit, Azienda Ospedaliera Pugliese‐Ciaccio, Catanzaro, Italy

  • Baxalta US Inc., a Takeda Company, Cambridge, United States

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Queen Elizabeth Hospital, University of Birmingham, Birmingham, United Kingdom

  • University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, United States

  • Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum Friedrichshain, Berlin, Germany

Locations

  • Germany

  • Austria

  • Italy

  • United States

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • NCT03199794

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved